You are here: Industry Insights > Vectura

News List

Vectura Signs Agreement with Aerami Therapeutics contractpharma
June 09, 2020
Will support the development of imatinib for the treatment of Pulmonary Arterial Hypertension.
Vectura wins patent litigation battle against GSK, awarded $89.7M pharmatimes
May 09, 2019
Vectura has confirmed that it has won the US GlaxoSmithKline (GSK) patent litigation trial and has been awarded $89.7million in damages by the trial jury.
Phase 3 failure of asthma therapy sends Vectura's ailing shares falling pharmafile
November 28, 2018
Vectura has announced it is terminating development of its severe asthma therapy VR475, an inhaled formulation of the corticosteroid budesonide, after it failed in Phase 3 trials to demonstrate...
Vectura takes £40 million hit as asthma drug fails trial pharmaphorum
November 28, 2018
Vectura has abandoned a late-stage drug in severe uncontrolled asthma after it failed a phase 3 trial, resulting in a decline in its already-depressed share price.
Vectura Group announces global agreement with Hikma to develop generic versions of GSK’s Ellipta® portfolio pharmafocusasia
November 12, 2018
Vectura Group plc, today announces signing an agreement with Hikma Pharmaceuticals PLC ("Hikma") for the global development and commercialisation of generic versions of GSK’s Ellipta® portfolio, utilising Vectura’s proprietary Open-Inhale-Close dry powder
Hikma, Vectura to develop generic rivals to GSK's Ellipta portfolio pharmatimes
November 12, 2018
Following interactions with US regulators, the firms believe the inhaler device has the potential to be developed as a substitutable drug-device combination for generic versions of the GSK Ellipta portfolio.
Vectura and Hikma to jointly develop generic versions of GSK’s Ellipta americanpharmaceuticalreviewpharmaceutical-technol
November 10, 2018
UK-based drug manufacturers Vectura Group and Hikma Pharmaceuticals have collaborated to develop and commercialise a generic version of GSK’s Ellipta inhaler products indicated for respiratory conditions.
Vectura allows Dynavax access to smart inhalers pharmatimes
August 17, 2017
Vectura has signed an exclusive global agreement with Dynavax Technologies allowing use of its proprietary smart nebuliser technology to deliver an investigational immunotherapeutic to lung cancer patients.
Vectura links with Novartis for inhaled asthma/COPD generic pharmatimes
June 30, 2017
Vectura links with Novartis for inhaled asthma/COPD generic
Vectura achieves £9 million royalty cap from GSK Ellipta products cphi-online
February 21, 2017
Company achieves the £9 million calendar year royalty cap on net sales of Ellipta products a year earlier than previously guided.

Previous page 1 2 Next page